Prot# CA180-035: Rndmzd 2-Arm, Mltctr, Opn-Lbl Phz 2 Study of BMS-354825 Admin'd Orally at Dose of 70mg 2x Daily or 140mg 1x Daily in Sbjts w/Chronic Myeloid Leukemia in Accelr'd Phz or in Myeloid or Lymphoid Blast Phz or w/Philadelphia Chromosome Positiv

  • Tallman, Martin Stuart (PD/PI)

Project: Research project

Project Details

Effective start/end date10/31/0511/21/11


  • Bristol-Myers Squibb Company (CA180-035)